Overview

Risperidone Maintenance Treatment in Schizophrenia

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This study set out to determine the duration of maintenance treatment with therapeutic risperidone dose in schizophrenia. In a multi-center, open label, randomized, controlled study design, patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months).
Phase:
Phase 4
Details
Lead Sponsor:
Capital Medical University
Treatments:
Risperidone